Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Turner's Syndrome Clear all
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Oct 5, 2026, 2:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

NCT00471731
View directory record Official record
Conditions
Turner Syndrome, Ovarian Failure, Premature, Sex Chromosome Aberrations, Menopause, Perimenopause
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 5, 2026, 2:46 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 5, 2026, 2:46 AM EDT
Not listed Phase 2 Interventional

Vosoritide for Short Stature in Turner Syndrome

NCT05849389
View directory record Official record
Conditions
Turner Syndrome, Short Stature
Interventions
Vosoritide
Drug
Lead sponsor
Roopa Kanakatti Shankar, MBBS, MS
Other
Eligibility
3 Years to 11 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 5, 2026, 2:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fertility Attitudes of Adolescents and Young Adults With Turner Syndrome and Their Parents/Guardians (The Fertility ConcepTS Study)

NCT05078892
View directory record Official record
Conditions
Fertility Perservation, Fertility
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 5, 2026, 2:46 AM EDT
Recruiting Phase 3 Interventional

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546
View directory record Official record
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 5, 2026, 2:46 AM EDT
Completed No phase listed Observational

National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions

NCT01322165
View directory record Official record
Conditions
Marfan Syndrome, Turner Syndrome, Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation, Bicuspid Aortic Valve Without Known Family History, Bicuspid Aortic Valve With Family History, Bicuspid Aortic Valve With Coarctation, Familial Thoracic Aortic Aneurysm and Dissections, Shprintzen-Goldberg Syndrome, Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo, Other Congenital Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
3,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
7
States / cities
Honolulu, Hawaii • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 5, 2026, 2:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes

NCT02213484
View directory record Official record
Conditions
Marfan Syndrome, Loeys-Dietz Syndrome, Thoracic Aortic Aneurysm and Dissection Syndromes, Ehlers-Danlos Type IV Syndrome, Turner Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Days to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 3 Interventional

The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome

NCT00029159
View directory record Official record
Conditions
Turner Syndrome
Interventions
estrogen, androgen, placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 5, 2026, 2:46 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873
View directory record Official record
Conditions
Obesity, Overweight, Craniopharyngioma
Interventions
Exenatide
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 3 Interventional

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

NCT00140998
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 beta estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 16 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 5, 2026, 2:46 AM EDT
Not listed No phase listed Observational

Turner Syndrome Prenatal Diagnosis Study

NCT01668251
View directory record Official record
Conditions
Turner Syndrome
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 3 Months · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

NCT01438073
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 5, 2026, 2:46 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study

NCT05548881
View directory record Official record
Conditions
Cardiovascular Phenotype, Metabolic Phenotype, Hypertensive Disease, Psychological Phenotype, Audio
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 5, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9

NCT05723835
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Sacramento, California • Centennial, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
LB54640, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Hormone Replacement Therapy to Treat Turner Syndrome

NCT00013546
View directory record Official record
Conditions
Osteoporosis, Turner's Syndrome
Interventions
TMTDS
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 2:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sex Differences in Early Brain Development; Brain Development in Turner Syndrome

NCT00877942
View directory record Official record
Conditions
Turner Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
2 Weeks to 2 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 5, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325
View directory record Official record
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 5, 2026, 2:46 AM EDT
Completed Phase 3 Interventional

Open-Label Extension Study of Setmelanotide

NCT06596135
View directory record Official record
Conditions
Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 5, 2026, 2:46 AM EDT
Completed No phase listed Observational

Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

NCT00770458
View directory record Official record
Conditions
Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Turner Syndrome
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • San Jose, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Oct 5, 2026, 2:46 AM EDT